Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06102512 · ClinicalTrials.gov registry record · Phase 1
A Study of [14C]-LOXO-783 in Healthy Adult Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06102512 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants.
The verdict
NCT06102512, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how much of the study drug, the radioactive substance 14C incorporated LOXO-783 (\[¹⁴C\]-LOXO-783) passes from blood into urine, feces and expired air in healthy adult participants when administered as a single dose. The study will also measure how much of the LOXO-783 and \[¹⁴C\]-LOXO-783 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts and will last up to approximately 72 and 61 days for part 1 and 2, respectively.
Interventions
- DRUG LOXO-783
- DRUG [¹⁴C]-LOXO-783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2024-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06102512
The ClinicalTrials.gov registry entry for NCT06102512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LOXO-783 is the first listed.
NCT06102512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06102512 about?
NCT06102512 is a clinical study titled "A Study of [14C]-LOXO-783 in Healthy Adult Participants". The main purpose of this study is to evaluate how much of the study drug, the radioactive substance 14C incorporated LOXO-783 (\[¹⁴C\]-LOXO-783) passes from blood into urine, feces and expired air in healthy adult participants when administered as a single dose. The study will also measure how much ...
What is the current status of trial NCT06102512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-10-23. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT06102512?
The interventions under investigation include: LOXO-783 (DRUG), [¹⁴C]-LOXO-783 (DRUG).
Who is sponsoring clinical trial NCT06102512?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.